GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » EBIT per Share

ZURA (Zura Bio) EBIT per Share : $-0.79 (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio EBIT per Share?

Zura Bio's EBIT per Share for the three months ended in Sep. 2024 was $-0.22. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.79.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Zura Bio's EBIT per Share or its related term are showing as below:

ZURA's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Zura Bio's EBIT for the three months ended in Sep. 2024 was $-19.32 Mil.


Zura Bio EBIT per Share Historical Data

The historical data trend for Zura Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio EBIT per Share Chart

Zura Bio Annual Data
Trend Dec21 Mar22 Dec23
EBIT per Share
- - -1.89

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.23 -0.18 -0.16 -0.22

Zura Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Zura Bio's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-62.638/33.064
=-1.89

Zura Bio's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

EBIT per Share(Q: Sep. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-19.319/87.336
=-0.22

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zura Bio  (NAS:ZURA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Zura Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Zura Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio Business Description

Traded in Other Exchanges
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Someit Sidhu director C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Ploos Van Amstel Arnout director C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-11
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192